Researcher at Gwangju Institute of Science and Technology, South Korea
Dr. Shibo Wei is a distinguished researcher with notable contributions to cardiovascular diseases, mitochondria and mitostasis, aging, metabolic disorders, drug screening, and bioinformatics. His impactful research, published in prestigious journals, spans multiple geographic regions and reflects his strong collaborative efforts with international experts. Dr. Wei’s applied research addresses critical medical challenges, offering valuable insights into therapeutic targets for age-related diseases and cancer. Although his work does not directly focus on environmental health, vector control, waste management, or water quality, his findings on metabolic and age-related diseases have broader implications for public health. His studies on the impact of cancer cachexia on gut microbiota further contribute to understanding infectious diseases. Recognized for his significant academic achievements and collaborations, Dr. Wei exemplifies the qualities of a leading scholar, making him a compelling candidate for the Research for Best Scholar Award.
Profile
Dr. Shibo Wei’s educational journey is a testament to his dedication and excellence in the medical field. He began his academic career at Jilin University, where he completed his undergraduate studies in Medicine from July 2011 to June 2016. During this time, he gained a strong foundation in medical sciences, which paved the way for his future endeavors. Following his undergraduate studies, Dr. Wei pursued an MD in Surgery at The Second Hospital of Jilin University, graduating in June 2019. This advanced training provided him with practical and clinical expertise, essential for his research and medical practice. In February 2021, he commenced his Ph.D. in Precision Medicine at Sungkyunkwan University, South Korea, a program he is set to complete in February 2024. This rigorous doctoral program has further refined his research skills and knowledge, particularly in cutting-edge areas like precision medicine, enhancing his ability to contribute significantly to medical research and innovation.
Professional Experience
Dr. Shibo Wei currently serves as a researcher and post-doctoral fellow at the Gwangju Institute of Science and Technology. His academic journey includes significant roles at Jilin University and The Second Hospital of Jilin University, where he completed his undergraduate studies and MD in surgery. Furthering his expertise, Dr. Wei pursued a Ph.D. in Precision Medicine at Sungkyunkwan University. His professional experience spans several research areas, including cardiovascular diseases, mitochondria and mitostasis, and metabolic disorders. Dr. Wei’s work integrates advanced bioinformatics and drug screening techniques, contributing to a deeper understanding of age-related diseases. His research has led to numerous high-impact publications, reflecting his role in advancing medical science and therapeutics. His collaborative efforts with international researchers enhance the global reach and applicability of his work, establishing him as a prominent figure in the field of precision medicine and molecular research.
Research Interest
Dr. Shibo Wei currently serves as a researcher and post-doctoral fellow at the Gwangju Institute of Science and Technology. His academic journey includes significant roles at Jilin University and The Second Hospital of Jilin University, where he completed his undergraduate studies and MD in surgery. Furthering his expertise, Dr. Wei pursued a Ph.D. in Precision Medicine at Sungkyunkwan University. His professional experience spans several research areas, including cardiovascular diseases, mitochondria and mitostasis, and metabolic disorders. Dr. Wei’s work integrates advanced bioinformatics and drug screening techniques, contributing to a deeper understanding of age-related diseases. His research has led to numerous high-impact publications, reflecting his role in advancing medical science and therapeutics. His collaborative efforts with international researchers enhance the global reach and applicability of his work, establishing him as a prominent figure in the field of precision medicine and molecular research.
Dr. Shibo Wei has made significant contributions to several critical areas of medical research, including cardiovascular diseases, mitochondria and mitostasis, aging, metabolic diseases, drug screening, and bioinformatics. His research has been widely published in prestigious journals, showcasing his innovative work in these domains. Notable papers include studies on gastrointestinal cancer, sarcopenic obesity, and therapeutic targets for age-related diseases.
Geographic Impact
Dr. Wei’s research has a broad geographic impact, spanning institutions in China, South Korea, and international collaborations. His work has been recognized and utilized globally, particularly in regions focusing on precision medicine and advanced medical research. His educational background from Jilin University and Sungkyunkwan University further emphasizes his international influence.
Collaborative Efforts
Dr. Wei is a highly collaborative researcher, co-authoring numerous papers with researchers from various institutions. This collaborative approach is evident in his publications, where he has worked with experts in different fields, including endocrinology, molecular medicine, and oncology. His ability to work effectively in multidisciplinary teams highlights his contribution to advancing medical research through collective efforts.
Applied Research
Dr. Wei’s research is highly applicable to real-world medical challenges. His studies on cardiovascular diseases, metabolic disorders, and cancer provide valuable insights for developing new therapeutic strategies. For example, his work on protein arginine methyltransferases and mitochondria-associated programmed cell death offers potential therapeutic targets for age-related diseases and cancer.
Specific Projects and Publications
Dr. Wei has been involved in numerous impactful projects, including:
- “The Implicated Role of GDF15 in Gastrointestinal Cancer” (European Journal of Clinical Investigation, 2024).
- “Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management” (Frontiers in Endocrinology, 2023).
- “Mitochondria-associated programmed cell death as a therapeutic target for age-related disease” (Experimental & Molecular Medicine, 2023).
These publications demonstrate his expertise in tackling complex medical problems and contribute to the broader understanding of disease mechanisms and treatment options.
Environmental Health
Dr. Wei’s research touches upon environmental health through his studies on the impact of metabolic and age-related diseases on public health. By exploring the underlying mechanisms of these diseases, his work indirectly contributes to improving environmental health by addressing the root causes and potential preventative measures.
Vector Control
While Dr. Wei’s primary research focus is not on vector control, his work on metabolic diseases and aging can contribute to understanding how these conditions might influence susceptibility to vector-borne diseases. His interdisciplinary approach may offer insights into integrated strategies for disease prevention and management.
Parasitology and Infectious Diseases
Dr. Wei has contributed to the field of infectious diseases through his work on the impact of cancer cachexia on gut microbiota composition and metabolism. This research is critical for understanding the interactions between chronic diseases and infectious agents, which can inform better treatment and prevention strategies.
Awards and Recognition
Dr. Wei’s work has garnered significant recognition, evidenced by his numerous publications in high-impact journals. His contributions to medical research have been acknowledged through collaborative projects and citations by peers, underscoring his influence and standing in the scientific community.
Conclusion
Dr. Shibo Wei is a strong candidate for the Research for Best Scholar Award. His extensive research contributions, broad geographic impact, collaborative efforts, and applied research in critical areas of medicine make him a deserving nominee. His work not only advances scientific knowledge but also offers practical solutions to pressing health issues, thereby benefiting communities globally.
Publications Top Notes
- Diversity and complexity of cell death: a historical review
- Authors: W. Park, S. Wei, B.S. Kim, B. Kim, S.J. Bae, Y.C. Chae, D. Ryu, K.T. Ha
- Year: 2023
- Citations: 61
- Mitochondria-associated programmed cell death as a therapeutic target for age-related disease
- Authors: T.T. Nguyen, S. Wei, T.H. Nguyen, Y. Jo, Y. Zhang, W. Park, K. Gariani, C.M. Oh, …
- Year: 2023
- Citations: 40
- Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
- Authors: S. Wei, T.T. Nguyen, Y. Zhang, D. Ryu, K. Gariani
- Year: 2023
- Citations: 37
- Overview of growth differentiation factor 15 in metabolic syndrome
- Authors: M. Asrih, S. Wei, T.T. Nguyen, H.S. Yi, D. Ryu, K. Gariani
- Year: 2023
- Citations: 22
- Poor management of hypertension is an important precipitating factor for the development of acute aortic dissection
- Authors: N. Dong, H. Piao, B. Li, J. Xu, S. Wei, K. Liu
- Year: 2019
- Citations: 21
- Development of a practical prediction score for acute renal injury after surgery for Stanford type A aortic dissection
- Authors: N. Dong, H. Piao, Y. Du, B. Li, J. Xu, S. Wei, K. Liu
- Year: 2020
- Citations: 11
- The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model
- Authors: S.M. Jeong, E.J. Jin, S. Wei, J.H. Bae, Y. Ji, Y. Jo, J.H. Jeong, S.J. Im, D. Ryu
- Year: 2023
- Citations: 4
- Novel surgical treatment of abdominal aortic aneurysm complicated with primary aorto-colonic fistula: a case report
- Authors: M. Huang, H. Piao, Y. Wang, W. Wang, S. Wei, C. Xie, K. Liu
- Year: 2018
- Citations: 2
- Gut microbiota-generated metabolites: missing puzzles to hosts’ health, diseases, and aging
- Authors: Y. Zhang, S. Wei, H. Zhang, Y. Jo, J.S. Kang, K.T. Ha, J. Joo, H.J. Lee, D. Ryu
- Year: 2024
- Citations: 1
- Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
- Authors: W. Park, J.H. Han, S. Wei, E.S. Yang, S.Y. Cheon, S.J. Bae, D. Ryu, H.S. Chung, …
- Year: 2024
- Citations: 1